SCHEMBL24253018

SCHEMBL24253018

COc1ccc(CNc2cnnc3cc(Br)cnc23)c(OC)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.46
APLNR P35414 1/20 0.45
CYP1A2 P05177 12/20 0.43
CYP3A4 P08684 12/20 0.43
CYP2D6 P10635 12/20 0.43
CYP2C19 P33261 11/20 0.43
TSHR P16473 10/20 0.43
ALDH1A1 P00352 5/20 0.43
CYP2C9 P11712 5/20 0.43
MAPK1 P28482 2/20 0.43
NPC1 O15118 1/20 0.43
PKM P14618 1/20 0.43
RAB9A P51151 1/20 0.43
LMNA P02545 4/20 0.42
HIF1A Q16665 2/20 0.42
MAPT P10636 2/20 0.42
HSD17B10 Q99714 5/20 0.41
ALOX15 P16050 3/20 0.41
GAA P10253 2/20 0.41
MEN1 O00255 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452098 1.00 KDM4C (0.46) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL30451812 0.83 KDM4C (0.47) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL24252810 0.83 KDM4C (0.47) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL30451322 0.82 KDM4C (0.45) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL24252877 0.82 KDM4C (0.45) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL24252952 0.81 CYP1A2 (0.43) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL30451328 0.81 CYP1A2 (0.43) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL25217123 0.81 KDM4C (0.44) KDM4CAPLNRCYP1A2CYP3A4CYP2D6
SCHEMBL21463802 0.79 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL24252425 0.79 KDM4C (0.44) KDM4CAPLNRCYP1A2CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 KDM4C 4542/4885APLNR 1122/4885CYP1A2 2977/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH KDM4C 3892/4885APLNR 964/4885CYP1A2 4150/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 KDM4C 4654/4885APLNR 490/4885CYP1A2 3838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.